PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT. This will follow the poster presentation of the VIP236 clinical data at the AACR Annual Meeting 2024.
The virtual investor event will include presentations by Ahmed Hamdy, MD, CEO of Vincerx Pharma, along with key opinion leaders, Uma Borate, MD, MBBS, Clinical Associate Professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and Vivek Subbiah, MD, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute.
To register and view the live webcast, please visit: https://edge.media-server.com/mmc/p/xhv7kxf7/. An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. Vincerx’s diverse pipeline consists of the next-generation antibody-drug conjugate, VIP943, in Phase 1; small molecule-drug conjugate, VIP236, in Phase 1; preclinical antibody-drug conjugate, VIP924; CDK9 inhibitor, enitociclib, in an NIH-sponsored Phase 1; and VersAptx™, its versatile and adaptable, next-generation bioconjugation platform.
Vincerx is based in Palo Alto, California, and has a research facility in Monheim, Germany. For more information, please visit www.vincerx.com and follow Vincerx on LinkedIn.
Vincerx, the Vincerx logo, and VersAptx are Vincerx trademarks.
Contacts
Gabriela Jairala
Vincerx Pharma, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Totyana Simien
Inizio Evoke Comms
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.05 |
Daily Volume: | 0 |
Market Cap: | US$1.820M |
March 18, 2025 January 29, 2025 December 27, 2024 November 12, 2024 October 07, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load